Ensign Peak Advisors, Inc Exelixis, Inc. Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 375,616 shares of EXEL stock, worth $12.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

375,616

Previous 484,356 22.45%

Holding current value

$12.5 Million

Previous $10.9 Million 10.44%

% of portfolio

0.02%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $2.39 Million - $3 Million	-108,740 Reduced 22.45%	375,616 $9.75 Million
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $594,334 - $693,390	-29,220 Reduced 5.69%	484,356 $10.9 Million
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $4.48 Million - $5.32 Million	222,266 Added 76.3%	513,576 $12.2 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $186,436 - $233,699	9,685 Added 3.44%	291,310 $6.99 Million
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $1.34 Million - $1.6 Million	70,480 Added 33.38%	281,625 $6.15 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $319,701 - $360,345	-17,595 Reduced 7.69%	211,145 $4.03 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $380,327 - $452,893	23,333 Added 11.36%	228,740 $4.44 Million
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $6.25 Million - $7.26 Million	-417,667 Reduced 67.03%	205,407 $3.29 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $2.86 Million - $4.07 Million	182,578 Added 41.45%	623,074 $9.77 Million
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $4.74 Million - $6.3 Million	272,046 Added 161.5%	440,496 $9.17 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $288,999 - $384,709	16,970 Added 11.2%	168,450 $3.82 Million
Q4 2021 Feb 11, 2022	SELL	$15.84 - $21.88 $1.47 Million - $2.03 Million	-92,920 Reduced 38.02%	151,480 $2.77 Million
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $156,317 - $202,732	-9,590 Reduced 3.78%	244,400 $5.17 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $113,892 - $162,178	6,345 Added 2.56%	253,990 $4.63 Million
Q1 2021 May 12, 2021	SELL	$20.53 - $25.22 $380,810 - $467,805	-18,549 Reduced 6.97%	247,645 $5.59 Million
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $7.51 Million - $10.1 Million	-408,467 Reduced 60.54%	266,194 $5.34 Million
Q3 2020 Nov 12, 2020	BUY	$20.67 - $26.94 $1.25 Million - $1.63 Million	60,651 Added 9.88%	674,661 $16.5 Million
Q2 2020 Aug 12, 2020	BUY	$16.46 - $27.42 $1.83 Million - $3.05 Million	111,072 Added 22.08%	614,010 $14.6 Million
Q1 2020 May 11, 2020	BUY	$14.46 - $21.8 $3.2 Million - $4.82 Million	221,147 Added 78.48%	502,938 $8.66 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $4.27 Million - $5.32 Million	281,791 New	281,791 $4.97 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Exelixis, Inc. Transaction History